Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 13/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25364988 | 1.00 | PKM (0.50) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL25366197 | 0.95 | PKM (0.49) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL25366200 | 0.95 | PKM (0.49) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL4828718 | 0.88 | CTSS (0.60) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL4828729 | 0.88 | CTSS (0.60) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL6803162 | 0.85 | CTSS (0.54) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL6801412 | 0.84 | HTT (0.56) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL6800711 | 0.81 | PKM (0.51) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL3872807 | 0.80 | PKM (0.50) | PKMSMN1; SMN2CTSSHTTCAPN1 | |
| SCHEMBL3872815 | 0.80 | PKM (0.50) | PKMSMN1; SMN2CTSSHTTCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161321-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | VESPER BIO APS (DK) | 2025-05-22 | — | — | US | claimed |
| EP-4486443-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | Vesper Bio Aps (DK) | 2025-01-08 | — | — | EP | claimed |
| CN-118922403-A | Amino acid based carbamates and/or ureases for the treatment of sortilin dependent diseases | 维斯珀生物应用有限公司 | 2024-11-08 | — | — | CN | claimed |
| WO-2023161505-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | INSUSENSE ApS (DK) | 2023-08-31 | — | — | WO | claimed |
| EP-4234014-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | Insusense ApS (DK) | 2023-08-30 | — | — | EP | claimed |
| US-20250161321-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | VESPER BIO APS (DK) | 2025-05-22 | — | — | US | disclosed |
| EP-4486443-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | Vesper Bio Aps (DK) | 2025-01-08 | — | — | EP | disclosed |
| CN-118922403-A | Amino acid based carbamates and/or ureases for the treatment of sortilin dependent diseases | 维斯珀生物应用有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023161505-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | INSUSENSE ApS (DK) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023161505-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | INSUSENSE ApS (DK) | 2023-08-31 | — | — | WO | disclosed |
| EP-4234014-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | Insusense ApS (DK) | 2023-08-30 | — | — | EP | disclosed |
| EP-4234014-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | Insusense ApS (DK) | 2023-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161321-A1 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | SORT1, SLC14A1, CTSA | PKM 4036/4885SMN1; SMN2 788/4885CTSS 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.